Filing Flows › 8-K events › Inovio Pharmaceuticals
Inovio Pharmaceuticals: regulation fd disclosure
Form 8-K filed Nov 2, 2026 · items 7.01, 8.01
FDA decisionsINOVIO Announces FDA Accelerated Approval of VOCERYQ ™ , an Immunotherapy to
What the filing says
INOVIO Announces FDA Accelerated Approval of VOCERYQ ™ , an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP)
Read the filing on SEC EDGAR →
What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →
Inovio Pharmaceuticals at a glance
Inovio Pharmaceuticals, Q1 2025: revenue $65K. The chart follows the revenue to costs, profit and cash.
Inovio Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.